Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Guan, Hongbing ^a   Singh, Narendra P ^a   Singh, Udai P ^a   Nagarkatti, Prakash S ^a   Nagarkatti, Mitzi ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; POLYPHENOL; RESVERATROL; TRANSCRIPTION FACTOR FKHR; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CANCER CELL; CANCER SUSCEPTIBILITY; CELL DAMAGE; CELL EXPANSION; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; INJECTION; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; METASTASIS; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VASCULAR DISEASE; VASCULAR LEAK SYNDROME; ANIMAL; CANCER TRANSPLANTATION; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; LYMPHOKINE ACTIVATED KILLER CELL; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ENDOTHELIAL CELLS; FEMALE; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG NEOPLASMS; MELANOMA; MICE; NEOPLASM TRANSPLANTATION; STILBENES; T-LYMPHOCYTES, REGULATORY;

EID: 84859984869     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035650     Document Type: Article

References (40)

1. Dutcher J, (2002) Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Williston Park) 16: 4-10.
2. Schwartz RN, Stover L, Dutcher J, (2002) Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 16: 11-20.
3. Baluna R, Vitetta ES, (1997) Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 37: 117-132.
4. McDermott DF, (2009) Immunotherapy of metastatic renal cell carcinoma. Cancer 115: 2298-2305.
5. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL, (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161: 1169-1188.
6. Cotran RS, Pober JS, Gimbrone MA Jr, Springer TA, Wiebke EA, et al. (1988) Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome. J Immunol 140: 1883-1888.
7. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES, (1999) Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A 96: 3957-3962.
8. Assier E, Jullien V, Lefort J, Moreau JL, Di Santo JP, et al. (2004) NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J Immunol 172: 7661-7668.
9. Damle NK, Doyle LV, (1989) IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers. Implications for vascular leak syndrome. J Immunol 142: 2660-2669.
10. Rosenstein M, Ettinghausen SE, Rosenberg SA, (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137: 1735-1742.
11. Lentsch AB, Miller FN, Edwards MJ, (1999) Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol Immunother 47: 243-248.
12. Melencio L, McKallip RJ, Guan H, Ramakrishnan R, Jain R, et al. (2006) Role of CD4(+)CD25(+) T regulatory cells in IL-2-induced vascular leak. Int Immunol 18: 1461-1471.
13. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
14. Greten TF, Manns MP, Korangy F, (2011) Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 11: 802-806.
15. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, et al. (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50: 799-807.
16. Li H, Han Y, Guo Q, Zhang M, Cao X, (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182: 240-249.
17. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI, (2004) Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172: 989-999.
18. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, et al. (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13: 828-835.
19. Elies J, Cuinas A, Garcia-Morales V, Orallo F, Campos-Toimil M, (2011) Trans-resveratrol simultaneously increases cytoplasmic Ca(2+) levels and nitric oxide release in human endothelial cells. Mol Nutr Food Res 55: 1237-1248.
20. Wang H, Yang YJ, Qian HY, Zhang Q, Xu H, et al. (2011) Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev.
21. Namasivayam N, (2011) Chemoprevention in experimental animals. Ann N Y Acad Sci 1215: 60-71.
22. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB, (2011) Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 1215: 150-160.
23. Singh NP, Singh UP, Hegde VL, Guan H, Hofseth L, et al. (2011) Resveratrol (trans-3,5,4′-trihydroxystilbene) suppresses EL4 tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and NF-kappaB. Mol Nutr Food Res 55: 1207-1218.
24. Osmond GW, Augustine CK, Zipfel PA, Padussis J, Tyler DS, (2012) Enhancing Melanoma Treatment with Resveratrol. J Surg Res 172: 109-115.
25. Gatouillat G, Balasse E, Joseph-Pietras D, Morjani H, Madoulet C, (2010) Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J Cell Biochem 110: 893-902.
26. Guan H, Nagarkatti PS, Nagarkatti M, (2007) Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma. J Immunol 179: 3715-3723.
27. McKallip RJ, Fisher M, Do Y, Szakal AK, Gunthert U, et al. (2003) Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. J Biol Chem 278: 43818-43830.
28. Mustafa A, McKallip RJ, Fisher M, Duncan R, Nagarkatti PS, et al. (2002) Regulation of interleukin-2-induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies. J Immunother 25: 476-488.
29. Rafi AQ, Zeytun A, Bradley MJ, Sponenberg DP, Grayson RL, et al. (1998) Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome. J Immunol 161: 3077-3086.
30. Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, Nagarkatti P, (2007) Resveratrol (trans-3,5,4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 72: 1508-1521.
31. Zhao Y, Yang J, Liao W, Liu X, Zhang H, et al. (2010) Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol 12: 665-675.
32. Medema RH, Jaattela M, (2010) Cytosolic FoxO1: alive and killing. Nat Cell Biol 12: 642-643.
33. Singh UP, Singh NP, Singh B, Hofseth LJ, Taub DD, et al. (2012) Role of resveratrol-induced CD11b(+) Gr-1(+) myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3(+) T cells and amelioration of chronic colitis in IL-10(-/-) mice. Brain Behav Immun 26: 72-82.
34. Yang Y, Paik JH, Cho D, Cho JA, Kim CW, (2008) Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells. Int Immunopharmacol 8: 542-547.
35. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, et al. (2008) Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol 181: 3291-3300.
36. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, et al. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
37. Donskov F, Bennedsgaard KM, Hokland M, Marcussen N, Fisker R, et al. (2004) Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 53: 729-739.
38. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, et al. (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69: 1553-1560.
39. Kusmartsev S, Gabrilovich DI, (2005) STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174: 4880-4891.
40. Narita Y, Wakita D, Ohkur T, Chamoto K, Nishimura T, (2009) Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed Res 30: 7-15.